Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Product Development

Prostate cancer disrupted

Why the treatment paradigm for prostate cancer could soon see a shake-up

Stephen Hansen, Associate Editor
March 1, 2019 10:14 PM UTC

Two imminent disruptions threaten to upend the treatment landscape for prostate cancer, changing who gets anti-androgen therapies and ushering in the first new MOAs in decades.

The launch of generic abiraterone means next generation anti-androgens in development will likely be pushed into earlier settings than the late-stage disease Johnson & Johnson’s branded Zytiga abiraterone has traditionally treated. ...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Target Profiles

Androgen receptor